m levels of hepcidin and interleukin 6 in Parkinson’s disease

• Autorzy: Kwiatek-Majkusiak J. , Geremek M. , Koziorowski D. , Tomasiuk R. , Szlufik S. , Friedman A.
• Języki publikacji: EN

Abstrakty

EN

Neurodegeneration in Parkinson’s disease (PD) includes processes of chronic inflammation and oxidative stress which are related to dysregulation in the homeostasis of iron metabolism. Hepcidin is a peptide hormone responsible for systemic iron homeostasis and simultaneously the inflammatory response protein, induced in response to interleukin 6 (IL‑6). We assessed the serum concentration of hepcidin and IL‑6 in the groups of patients with PD treated only pharmacologically with optimal individualized therapy (MT) and treated additionally with deep brain stimulation (DBS), compared to the control group. The serum concentrations of hepcidin and IL‑6 in the group of all PD patients were significantly higher than in the control group. In the group of PD patients treated with DBS hepcidin and IL‑6 concentrations were significantly higher compared to the control group. Additionally, the positive correlations between serum hepcidin and IL‑6 were found in the PD (MT and DBS) and PD‑DBS group. The obtained results may indicate the influence of immunological mechanisms on iron metabolism and oxidative stress, in particular when the inflammatory process is more active in the DBS‑treated group. This effect can be protective as well as neurodegenerative.

• Wydawca: -
• Czasopismo: Acta Neurobiologiae Experimentalis
• Rocznik: 2020
• Tom: 80
• Numer: 3
• Opis fizyczny: p.297-304,fig.,ref.

Twórcy

autor

Kwiatek-Majkusiak J.

• Department of Neurology, Faculty of Health Science, Medical University of Warsaw, Warsaw, Poland

autor

Geremek M.

• Department of Neurology, Faculty of Health Science, Medical University of Warsaw, Warsaw, Poland

autor

Koziorowski D.

• Department of Neurology, Faculty of Health Science, Medical University of Warsaw, Warsaw, Poland

autor

Tomasiuk R.

• Biochemistry Laboratory, Mazovia Brodnowski Hospital, Warsaw, Poland

autor

Szlufik S.

• Department of Neurology, Faculty of Health Science, Medical University of Warsaw, Warsaw, Poland

autor

Friedman A.

• Department of Neurology, Faculty of Health Science, Medical University of Warsaw, Warsaw, Poland

Bibliografia

• Blum‑Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P (1995) Interleukin‑1 beta and interleukin‑6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. Neurosci Lett 202: 17–20.
• Brodacki B, Staszewski J, Toczyłowska B, Kozłowska E, Drela N, Chalimoniuk M, Stepien A (2008) Serum interleukin (IL‑2, IL‑10, IL‑6, IL‑4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci Lett 441: 158–162.
• De Domenico I, Zhang TY, Koening CL, Branch RW, London N, Lo E, Daynes  RA, Kushner JP, Li D, Ward DM, Kaplan J (2010)  Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J Clin Invest 120: 2395–2405.
• Deuschl G, Schade‑Brittinger C, Krack P (2006) A randomized trial of deep‑brain stimulation for Parkinson’s disease. N Engl J Med 355: 896–908.
• DiLorenzo DJ, Jankovic J, Simpson R, Takei H, Powell SZ (2010) Long‑term deep brain stimulation for essential tremor: 12‑year clinicopathologic follow‑up. Mov Disord 25: 232–238.
• Du F, Qian C, Ming Qian Z, Wu XM, Xie H, Yung WH, Ke Y (2011) Hepcidin directly inhibits transferrin receptor 1 expression in astrocytes via a cyclic AMP‑protein kinase a pathway. Glia 59: 936–945.
• Griffith RW, Humphrey DR (2006) Long‑term gliosis around chronically implanted platinum electrodes in the Rhesus macaque motor cortex. Neurosci Lett 406: 81–86.
• Hirshler YK, Polat U, Biegon A (2010) Intracranial electrode implantation produces regional neuroinflammation and memory deficits in rats. Exp Neurol 222: 42–50.
• Huang YH, Yang YL, Tiao MM, Kuo HC, Huang LT and Chuang JH (2012) Hepcidin protects against lipopolysaccharide-induced liver injury in a mouse model of obstructive jaundice. Peptides 35: 212–217.
• Joe EH, Choi DJ, An J, Eun JH, Jou I, Park S (2018) Astrocytes,  microglia, and Parkinson’s disease. Exp Neurobiol 27: 77–87.
• Kang J, Jiang L, Goldman SA, Nedergaard M (1998) Astrocyte‑mediated potentiation of inhibitory synaptic transmission. Nat Neurosci 1: 683–692.
• Ke Y, Ming Qian Z (2003) Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol 2: 246–253.
• Kwiatek‑Majkusiak  J, Geremek  M, Koziorowski D, Tomasiuk R, Szlufik S, Friedman A (2018) Higher serum levels of pro‑hepcidin in patients with Parkinson’s disease treated with deep brain stimulation. Neurosci Lett 684: 205–209.
• Li  L, Holscher C, Chen BB, Zhang ZF, Liu YZ (2011) Hepcidin treatment modulates the expression of divalent metal transporter‑1, ceruloplasmin, and ferroportin‑1 in the rat cerebral cortex and hippocampus. Biol Trace Elem Res 143: 1581–1593.
• Marques F, Falcao AM, Sousa J C, Coppola G, Geschwind D, Sousa N, Correia-Neves M and Palha J A (2009) Altered iron metabolism is part of the choroid plexus response to peripheral inflammation. Endocrinology 150: 2822–2828.
• Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T (1996) Interleukin (IL)‑1, IL‑2, IL‑4, IL‑4, IL‑6 and trans forming growth factor‑levels are elevated in ventricular cerebrospinal fluid in Juvenile parkinson‑ ism and Parkinson’s disease. Neurosci Lett 211: 13–16.
• Nagatsu T, Sawada M (2005) Inflammatory process in Parkinson’s disease: role for cytokines. Curr Pharm Des 11: 999–1016.
• Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T (2004) IL‑6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J  Clin Invest 113: 1271–1276.
• Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T (2003) Hepcidin, a  putative mediator of anemia of inflammation, is a  type II acute phase protein. Blood 101: 2461–2463.
• Orlowski D, Michalis A, Glud AN, Korshøj AR, Fitting LM, Mikkelsen TW, Mercanzini A, Jordan A, Dransart A, Sørensen JCH (2017) Brain tissue reaction to deep brain stimulation – a longitudinal study of DBS in the Goettingen minipig. Neuromodulation 20: 417–423.
• Pietrangelo A, Dierssen U, Valli L, Garuti C, Rump A, Corradini E, Ernst M, Klein C, Trautwein C (2007) STAT3 Is required for IL‑6‑gp130–dependent activation of hepcidin in vivo. Gastroenterology 132: 294–300 .
• Qian ZM, He X, Liang T, Wu KC, Yan YC, Lu LN, Yang G, Luo QQ, Yung WH, Ke  Y (2014) Lipopolysaccharides upregulate hepcidin in neuron via microglia and the IL‑6/STAT3 signaling pathway. Mol Neurobiol 50: 811–820.
• Qin XY, Zhang SP, Cao C, Loh YP, Cheng Y (2016) Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis. JAMA Neurol 73: 1316–1324.
• Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, Di Nicola M, Onofrj M (2009) Peripheral cytokines profile in Parkinson’s disease. Brain Behav Immun 23: 55–63.
• Ruchala  P,  Nemeth  E (2014) The  pathophysiology  and  pharmacology of hepcidin. Trends Pharmacol Sci 35: 155–161.
• Sawada M, Imamura K, Nagatsu T (2006) Role of cytokines in inflammatory process in Parkinson’s disease. J Neural Transm 70: 373–381.
• Su Y, Zhang K, Schluesener HJ (2010) Antimicrobial peptides in the brain. Arch Immunol Ther Exp 58: 365–377.
• Urrutia PJ, Hirsch EC, González‑Billault C, Núñez MT (2017) Hepcidin atten‑ uates amyloid beta‑induced inflammatory and pro‑oxidant responses in astrocytes and microglia. J Neurochem 142: 140–152.
• Wang SM, Fu LJ, Duan XL, Crooks DR, Yu P, Qian ZM, Di XJ, Li J, Rouault TA, Chang YZ (2010) Role of hepcidin in murine brain iron metabolism. Cell Mol Life Sci 67: 123–133.
• Wang Q, Du F, Qian ZM, Ge XH, Zhu L, Yung WH, Yang L, Ke Y (2008) Lipo‑ polysaccharide induces a significant increase in expression of iron regulatory hormone hepcidin in the cortex and substantia nigra in rat brain. Endocrinology 149: 3920–3925.
• Weaver FM, Follett K, Stern M (2009) Bilateral deep brain stimulation vs. best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 301: 63–73. Williams A, Gill S, Varma T (2010) Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial): a randomised, open‑label trial. Lancet Neurol 9: 581–591.
• Wrighting DM, Andrews NC (2006) Interleukin‑6 induces hepcidin expression through STAT3. Blood 108: 3204–3209.
• Verga Falzacappa MV, Vujic Spasic  M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU (2007) STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 109: 353–358.

Identyfikatory

DOI

10.21307/ane‑2020‑026